Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
In this meta-analysis, we aimed to estimate and compare the efficacy of add-on treatment of antidepressants with esketamine nasal spray and second-generation antipsychotics in patients with nonpsychotic major depressive disorder and inadequate response to antidepressants. Searching for acute-phase, double-blind, placebo-controlled, randomized trials, we found 22 second-generation antipsychotic (n = 8363) and 3 intranasal esketamine (n = 641) studies. Mean change in the Montgomery Åsberg Depression Rating Scale total score served as outcome. We determined a higher mean difference (vs placebo) for the pooled esketamine nasal spray trials (mean difference = 4.09, 95% confidence interval: 2.01 to 6.17) than for the pooled second-generation antipsychotic augmentation trials (mean difference = 2.05, 95% confidence interval: 1.51 to 2.59). Thus, the effect size for intranasal esketamine was nearly twice as high as those for the second-generation antipsychotics. This indicates high efficacy of add-on esketamine nasal spray in treatment-resistant major depressive disorder compared with other well-established, evidence-based pharmacological options such as augmentation with second-generation antipsychotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Meta- analytic data also indicate that glutamatergic treatment strategies may be superior to antipsychotic agents in adults with TRD 200,201 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [200]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 1×
“Mean change (from study baseline to endpoint) in the Montgomery Åsberg Depression Rating Scale (MADRS) total score (Montgomery and Asberg, 1979) served as outcome.”
MethodCumpston, M., Li, T., Page, M. J., Chandler, J., Welch, V. A., Higgins, J. P., & Thomas, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.ed000142 · Cited by 7,218
Nelson, J. C., & Papakostas, G. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030312 · Cited by 552 · cited 2×
“Add-on treatment with second-generation antipsychotics (SGAs) represents a well-established, evidence-based mainstay in the pharmacotherapy of treatment-resistant major depressive disorder (MDD) (Nelson and Papakostas, 2009; Blier, 2014; Zhou et al., 2015; Bauer et al., 2017).”
BackgroundPapakostas, G. I., & Fava, M. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.08.009 · Cited by 382 · cited 2×
“This increased response preferentially affects placebo groups rather than active treatment groups, resulting in a lower verum-placebo separation at study endpoint (Papakostas and Fava, 2009; Sinyor et al., 2010).”
BackgroundPapakostas, G. I., Fava, M., & Thase, M. E. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.08.010 · Cited by 284 · cited 1×
“…as evidence-based strategy in resistant MDD (Souery et al., 2011; Bauer et al., 2017; Dold and Kasper, 2017; Bartova et al., 2019), there is some evidence that at least some patients appear to benefit even from a within-class switch of the antidepressant compound (Papakostas et al., 2008).”
BackgroundInternational trends in antipsychotic use: A study in 16 countries, 2005–2014
Hálfdánarson, Ó., Zoëga, H., Aagaard, L., Bernardo, M., Brandt, L., Fusté, A. C., Furu, K., Garuoliené, K., Hoffmann, F., Huybrechts, K. F., et al. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.07.001 · Cited by 282
A Model of Placebo Response in Antidepressant Clinical Trials
Rutherford, B. R., & Roose, S. P. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12040474 · Cited by 268 · cited 2×
“…be considered that investigations focusing on the mechanisms of placebo response in clinical trials revealed an association between high likelihood for receiving active treatment and increased response, mainly due to enhanced hope induction (Rutherford and Roose, 2013; Kasper and Dold, 2015).”
BackgroundZhou, X., Keitner, G. I., Qin, B., Ravindran, A. V., Bauer, M., Del Giovane, C., Zhao, J., Liu, Y., Fang, Y., Zhang, Y., et al. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv060 · Cited by 197 · cited 1×
“Add-on treatment with second-generation antipsychotics (SGAs) represents a well-established, evidence-based mainstay in the pharmacotherapy of treatment-resistant major depressive disorder (MDD) (Nelson and Papakostas, 2009; Blier, 2014; Zhou et al., 2015; Bauer et al., 2017).”
Background
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationMcIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
Self-citationNovel and emerging treatments for major depression
Marwaha, S., Palmer, E., Suppes, T., Cons, E., Young, A. H., & Upthegrove, R. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02080-3 · Cited by 588
Kasper, S., Cubała, W. J., Fagiolini, A., Ramos-Quiroga, J. A., Souery, D., & Young, A. H. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1836399 · Cited by 85
Self-citationEsketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240515 · Cited by 90
Bahji, A., Zarate, C. A., & Vazquez, G. H. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2047928 · Cited by 73
Xin, N., Yan, W., & Jin, S. (2022) · BioMed Research International · doi:10.1155/2022/5095282 · Cited by 29
“(22) suggested that propofol should be combined with ketamine because of its analgesic effect and no cardiopulmonary inhibition.”
BackgroundRetractedTurkoz, I., Nelson, J. C., Wilkinson, S. T., Borentain, S., Macaluso, M., Trivedi, M. H., Williamson, D., Sheehan, J. J., Salvadore, G., Singh, J. B., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115165 · Cited by 25
“Additionally, a recent publication estimated esketamine to have twice the effect size of SGA augmentation, with a higher mean difference found for add-on pharmacotherapy with ESK (4.09 MADRS total score points) compared with SGAs (2.05 points) (Dold et al., 2020).”
ResultInfluentialEarly effects predict trajectories of response to esketamine in treatment-resistant depression
Estrade, I., Petit, A., Sylvestre, V., Danon, M., Leroy, S., Perrain, R., Vinckier, F., Mékaoui, L., Gaillard, R., Advenier-Iakovlev, E., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.09.030 · Cited by 19
Huang, C., Hu, L., Wu, L., Geng, F., Wong, G. T. C., Zhang, Y., Reif, A., Bao, Y., Xue, Q., & Lü, L. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03320-6 · Cited by 17
Key considerations in the pharmacological management of treatment-resistant depression
Yavi, M., Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1951225 · Cited by 15
“Comparisons of meta-analytic data have been attempted and some have highlighted the significant effect size for esketamine compared to atypical antipsychotics [115], but these analyses are in part limited by variability in how TRD is”
BackgroundIs treatment-resistant depression really resistant?
KASPER, S. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.02.001 · Cited by 13
Self-citationTreatment-resistant depression and intranasal esketamine: Spanish consensus on theoretical aspects
Mora, F., Ramos‐Quiroga, J. A., Baca‐García, E., Crespo, J. M., Gutiérrez-Rojas, L., Madrazo, A., Pérez-Costillas, L., Sáiz, P. A., Tordera, V., & Vieta, E. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1623659 · Cited by 11
Oliveira-Maia, A. J., Rive, B., Morrens, J., Godinov, Y., Cabrieto, J., Perualila, N. J., & Mulhern-Haughey, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1250987 · Cited by 9
“…antidepressant medications or the augmentation of at least one antidepressant with a substance without primary antidepressant properties for MDD, such as second generation antipsychotics (e.g., aripiprazole, quetiapine and risperidone) or mood stabilizers (e.g., lithium and lamotrigine) (6, 11–14).”
BackgroundResultPerugi, G., Calò, P., Filippis, S. D., Rosso, G., Vita, A., Adami, M., Ascione, G., Morrens, J., & Delmonte, D. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.769693 · Cited by 9
Bartova, L., Fugger, G., Dold, M., Kautzky, A., Fanelli, G., Zanardi, R., Albani, D., Weidenauer, A., Rujescu, D., Souery, D., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.03.068 · Cited by 7
Self-citationGałuszko‐Węgielnik, M., Włodarczyk, A., Cubała, W. J., Wilkowska, A., Górska, N., & Słupski, J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.705190 · Cited by 7
“The observed effect of ketamine efficacy in subsequent series shall be emphasized as being in line with the esketamine nasal spray studies showing the need for rather continuous than intermittent maintenance administration and with add-on to monoaminergic antidepressants (16).”
ResultOliveira-Maia, A. J., Morrens, J., Rive, B., Godinov, Y., Cabrieto, J., Perualila, N. J., Barbreau, S., & Mulhern-Haughey, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1250980 · Cited by 7
Ketamine and Esketamine for Treatment-Resistant Depression: Response to Reus, Mattes, and Schatzberg
McIntyre, R. S. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21060653r · Cited by 7
Wang, L., Chen, X., Gu, X., Smedt, H. D., Popova, V., Fu, D., Canuso, C. M., Drevets, W. C., & Chen, G. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s417027 · Cited by 6
Fugger, G., Bartova, L., Dold, M., Fabbri, C., Fanelli, G., Zanardi, R., Kautzky, A., Zohar, J., Souery, D., Mendlewicz, J., et al. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110480 · Cited by 6
Self-citationThornton, N. L. R., Black, W., Bognar, A., Dagge, D., Gitau, T., Hua, B., Joks, G., King, J., Lord, A., Scott, E. M., et al. (2023) · Asia-Pacific Psychiatry · doi:10.1111/appy.12550 · Cited by 5
“…efficacy and tolerability of esketamine in this indication has been shown in three short-term studies (the TRANSFORM series), and two long-term studies (the SUSTAIN series) (Daly et al., 2019; Dold et al., 2020; Fedgchin et al., 2019; Ochs-Ross et al., 2020; Popova et al., 2019; Wajs et al., 2020).”
BackgroundBahji, A., Vázquez, G. H., & Zarate, C. A. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.12.069 · Cited by 5
“While perfect congruence across trials cannot exist given the lack of standardization, several statistical methods fortunately allow researchers to manage deviations from the ideal scenario (Dold et al., 2020; McIntyre et al., 2020; Nelson and Papakostas, 2009; Witt et al., 2020; Xu et al., 2016).”
BackgroundRamos‐Quiroga, J. A., Mora, F., Arostegui, S., Cardoner, N., Etxeandia-Pradera, J.-I., Gómez-Juanes, R., Gómez‐Revuelta, M., Montes, J. M. G., & Vieta, E. (2025) · The European Journal of Psychiatry · doi:10.1016/j.ejpsy.2025.100313 · Cited by 4
Canuso, C. M., Bossie, C. A., Fu, D., Lane, R., Doherty, T., Lignugaris, A., Fagiolini, A. M., Llorca, P., McIntyre, R. S., Reif, A., et al. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250250 · Cited by 2
Regen, F., & Benkert, O. (2023) · Springer eBooks · doi:10.1007/978-3-662-67685-1_1 · Cited by 1
Benicio, L. A. D. O., da Silva, J. C. P., Bertazo, M. M., Roma, T. M., del Corsso, C., Alves, A. C., da Silva, J. A. L., Vieira, A. D., Barraza, J. P. P., MOREIRA, J. D., et al. (2025) · Caderno Pedagógico · doi:10.54033/cadpedv22n7-044 · Cited by 1
Eckert, D., & Kasper, S. F. (2026) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2026.2617195 · Cited by 3
“Next to comparisons between SGA and lithium, recently, meta-analytic evidence towards indirect comparisons between augmentation strategies involving Ketamine has emerged (Carter et al. 2020; Dold et al. 2020; Vázquez et al. 2021; oliveira-Maia et al. 2023).”
Self-citationWang, L., Xiong, R., Liu, H., Zhang, S., Xu, L., & Lai, X. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05108-z · Cited by 1
“Besides, the add-on intranasal esketamine is reported to be more effective than other antipsychotics augmentation in TRD treatment (Dold et al. 2020).”
Regen, F. (2026) · Springer eBooks · doi:10.1007/978-3-662-72452-1_1 · Cited by 1
Winhusen, T. M., Lofwall, M. R., Nunes, E. V., Kropp, F. B., Otterstatter, M. C., Fanucchi, L. C., Vena, A. A., & Ghitza, U. E. (2026) · Contemporary Clinical Trials · doi:10.1016/j.cct.2026.108437 · Cited by 1
New Progress in the Treatment of Refractory Depression with Esticketamine
孙, 诗. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.125592 · Cited by 1
Kasper, S. F. (2021) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Self-citationPharmakotherapie: Therapieresistenz
Regen, F. (2022) · Elsevier eBooks · doi:10.1016/b978-3-437-23031-8.00017-0
Eficácia da esketamina intranasal na depressão resistente: uma revisão de escopo
Guerra, G. M., Galvão, L. D. F. B., de Siqueira, M. C. C., do Rêgo, M. P. P., Florentino, R. B., de Oliveira, P. G. G., & Silva, H. R. D. S. E. (2025) · Revista Neurociências · doi:10.34024/rnc.2025.v33.19845
Ketamine for depression and other psychiatric diseases
Roth, W. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29930-8.00005-9
Arminen, H. (2022) · UTUPub (University of Turku)
A Presentation of Evidence and Effectiveness of Esketamine Treatments to Psychiatric Providers
Nango, M., & Nango, M. (2024) · UA Campus Repository (The University of Arizona)
da Silva, S. J. L. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Residual atypical psychotic disorder and neuroborreliosis: a case report
Milasauskiene, E., & Steiblienė, V. (2021) · Lithuanian University of Health Sciences
Young, A. H., Bartova, L., Cardoner, N., Demyttenaere, K., Fagiolini, A. M., Godinov, Y., Dzib, J. F. G., von Holt, C., McIntyre, R. S., Oliveira-Maia, A. J., et al. (2026) · European Psychiatry · doi:10.1192/j.eurpsy.2026.12229
“Esketamine nasal spray (NS), administered in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin norepineph-rinereuptakeinhibitor(SNRI),isapprovedinEuropeforthetreatment ofTRD[24,25].”
Self-citationMeta analytic evidence on esketamine in major depressive disorder: An umbrella review
Tatlı, S. Z., Ceylan, D., & Cankorur, V. Ş. (2026) · Journal of Clinical Psychiatry · doi:10.5505/kpd.2026.68856
Perugi, G., Calò, P., Filippis, S. D., Rosso, G., Vita, A., Adami, M., Ascione, G., Morrens, J., & Delmonte, D. (2021) · doi:10.3389/fpsyt.2021.769693.s001
Oliveira-Maia, A. J., Rive, B., Morrens, J., Godinov, Y., Cabrieto, J., Perualila, N., & Mulhern-Haughey, S. (2023) · doi:10.3389/fpsyt.2023.1250987.s002
Metadata
- Authors
- Dold, M., Bartova, L., & Kasper, S.
- Affiliations
- Medical University of Vienna (AT)
- Corresponding author
- Kasper, Siegfried
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-06-22
- Volume
- 23
- Issue
- 7
- Pages
- 440-445
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC7387762
- OpenAlex
- W3036507891
- Cited by
- 34
- References
- 23
- Citations by year
- 2026: 4 · 2025: 7 · 2023: 9 · 2022: 6 · 2021: 6 · 2020: 2
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Servier
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- esketamine, intranasal esketamine, treatment-resistant depression, major depressive disorder, atypical antipsychotics, antidepressant augmentation, adjunctive therapy, treatment response
- MeSH terms
- Administration, Intranasal, Antidepressive Agents, Major Depressive Disorder, Drug Therapy, Combination, Humans, Ketamine, Antipsychotic Agents, Randomized Controlled Trials as Topic, Treatment Outcome, Nasal Sprays, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.